Importantly, agents such as the sodium-glucose cotransporter-2 (SGLT2) inhibitors, whose administration in HF patients has been recently shown to be a very promising intervention strategy [198,199], show beneficial effects in both the fibroblast and the macrophage compartment in preclinical models [200,201], further underlining the importance of consideration of these two cell types in tandem when examining or planning modes to orchestrate cardiac repair. The gene discussed is SLC5A2; the disease is hydrops fetalis.